{"id":"ropinirole-cr-rls","safety":{"commonSideEffects":[{"rate":"20–30%","effect":"Nausea"},{"rate":"15–25%","effect":"Dizziness"},{"rate":"10–20%","effect":"Somnolence"},{"rate":"10–15%","effect":"Headache"},{"rate":"10–15%","effect":"Fatigue"},{"rate":"5–10%","effect":"Orthostatic hypotension"},{"rate":"5–10%","effect":"Hallucinations"}]},"_chembl":{"chemblId":"CHEMBL1200411","moleculeType":"Small molecule","molecularWeight":"296.84"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ropinirole binds to and activates dopamine D2 and D3 receptors in the central nervous system. In restless legs syndrome, dopaminergic dysfunction contributes to the characteristic sensations and involuntary movements; dopamine agonism helps restore normal motor control and reduces the urge to move the legs. The CR (controlled-release) formulation provides sustained drug delivery for once-daily dosing.","oneSentence":"Ropinirole is a dopamine D2/D3 receptor agonist that stimulates dopamine signaling in the brain to reduce the abnormal motor symptoms of restless legs syndrome.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:38.305Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Restless legs syndrome (RLS)"}]},"trialDetails":[{"nctId":"NCT00256854","phase":"PHASE3","title":"Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11-14","conditions":"Restless Legs Syndrome, Restless Legs Syndrome (RLS)","enrollment":135},{"nctId":"NCT00530790","phase":"PHASE2","title":"Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-23","conditions":"Restless Legs Syndrome","enrollment":35},{"nctId":"NCT00419692","phase":"PHASE1","title":"Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-24","conditions":"Restless Legs Syndrome","enrollment":32},{"nctId":"NCT00363727","phase":"PHASE3","title":"Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-12","conditions":"Parkinson's Disease, Parkinson Disease, Dyskinesias","enrollment":209},{"nctId":"NCT00373542","phase":"PHASE4","title":"12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10","conditions":"Restless Legs Syndrome (RLS), Restless Legs Syndrome","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ropinirole CR-RLS","genericName":"ropinirole CR-RLS","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ropinirole is a dopamine D2/D3 receptor agonist that stimulates dopamine signaling in the brain to reduce the abnormal motor symptoms of restless legs syndrome. Used for Restless legs syndrome (RLS).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}